Wire · regulatory
FDA Advisory Panel Backs Approval of GRAIL's Galleri Multi-Cancer Early Detection Test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
An FDA advisory panel voted 7-2 in favour of approving GRAIL's Galleri multi-cancer early detection blood test for adults aged 50 and older, supporting its safety, effectiveness, and benefit-risk profile. The test aims to identify multiple cancers early by detecting cancer-specific methylation patterns before symptoms appear, complementing standard screening.
This Wire brief sits within Fusion42's coverage of Diagnostics, and 10 sources have reported it between 21 Sep 2026 and 3 Oct 2026.
◆ ◆ The Wire takeaway
You must plan for Galleri’s FDA approval to open new market demand for multi-cancer blood tests targeting adults 50+. This shifts traditional cancer screening reliance and invites competition in molecular diagnostics.
◆ Coverage
10 sources · first reported 21 Sep 2026 · latest 3 Oct 2026
◆ Related on Wire
◆ Topics